A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
← catalyst calendarNCT06158854 · readout ≤ 559 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
76estimated
Sites
23
Countries
Australia, France, Greece +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-01 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Immunoglobulin Light Chain (AL) Amyloidosis
Intervention
- Drug: ABBV-383 (Etentamig) — also filed as TNB-383B
Primary outcomes
what the primary-completion date above is the date OFDose Escalation Only: Number of Participants with Dose-Limiting Toxicities (DLT)
measured Up to 28 Days
Dose Expansion Only: Percentage of Participants who Achieve Hematologic Complete Response (CR)
measured Up to 4 years
Dose Expansion Only: Number of Participants with DLTs
measured Up to 4 years
Number of Participants with Adverse Events (AEs)
measured Up to 4 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed